The Gene-to-Patient Market Size is valued at USD 134.6 billion in 2023 and is predicted to reach USD 341.4 billion by the year 2031 at a 12.5% CAGR during the forecast period for 2024-2031.
The gene-to-patient method intends to diagnose, treat, or prevent genetic diseases by creating and administering gene therapies that correct genetic information within a patient's cells. Beginning with the creation of gene therapy and continuing through its clinical use and patient care, this encompasses the whole process. The gene-to-patient market is driven by progress in genetic research and biotechnological innovations.
Additionally, the trend is sped up even more by a rising desire for personalized medicine, higher healthcare costs, and more people with chronic diseases. Gene-to-patient is also being supported by regulatory frameworks that are friendly and clinical studies that are growing, which is driving market growth. Moreover, the market's growth in developing countries will also be affected by the increasing concern for the accessibility and cost of healthcare around the world. The gene-to-patient business has great potential for future growth as the sector adjusts to new regulations and creates ground-breaking solutions.
However, the market growth is hampered by the strict regulatory criteria of gene-to-patient, lack of awareness, and high cost of treatment. In addition, the gene-to-patient business was greatly affected by the COVID-19 pandemic, which sped up the development of genetic technologies and vaccine research. Quick progress and partnerships in the field of genetic disorders were made possible by enhanced financing and regulatory flexibility. Furthermore, factors driving market expansion include an uptick in genetics disorders cases and a surge in research and development efforts related to the creation of these medications. Gene-to-patient therapy is in high demand because the incidence of long-term problems is on the rise worldwide.
Competitive Landscape
Some Major Key Players In The Gene-to-Patient Market:
- Illumina
- Thermo Fisher Scientific
- Roche Diagnostics
- Qiagen
- BioRad Laboratories
- Abbott Laboratories
- PerkinElmer
- Invitae
- Myriad Genetics
- Merck
- Guardant Health
- Foundation Medicine
- Genomic Health
- Agilent Technologies
- Laboratory Corporation of America (LabCorp)
- Exact Sciences
- Genscript Biotech Corporation
- CRISPR Therapeutics AG
- Editas Medicine
- Intellia Therapeutics Inc.
- Beam Therapeutics Inc.
- Caribou Biosciences Inc.
- Lonza Group Ltd.
- Other Market Players
Market Segmentation:
The gene-to-patient market is segmented based on type, application, end-user, technology, and distribution channel. Based on type, the market is segmented into gene therapy, gene editing, and gene silencing. By application, the market is divided into cancer treatment, genetic disorders, cardiovascular diseases, rare diseases, and infectious diseases. The end user market is categorized into hospitals, research institutes, biopharmaceutical companies, and diagnostic laboratories. By technology, the market is segmented into CRISPR, viral vector technology, non-viral delivery technology, and antisense oligonucleotide technology. The distribution channel segment includes direct sales, online sales, and third-party distributors.
Based On The Type, The Gene Therapy Gene-To-Patient Market Is Accounted As A Major Contributor To The Gene-To-Patient Market
The gene therapy gene-to-patient market is expected to lead with a major market share because biotechnology and genetic engineering have come a long way, greatly improving the effectiveness of treatments for genetic illnesses. Additionally, important factors propelling the market forward include an uptick in gene therapy awareness among patients, an increase in healthcare R&D spending, the frequency of chronic diseases, and the number of regulatory approvals for the treatment. Partnerships between biotech and pharmaceutical businesses to create new treatments are fueling this industry's expansion.
Hospitals Segment To Witnessed Growth At A Rapid Rate
Hospitals are growing rapidly in the gene-to-patient market because they are becoming more reliant on cutting-edge gene therapies to cure intricate gene diseases. Additionally, government financing for the integration of state-of-the-art medical technology, partnerships with biotech companies for clinical studies, and improved infrastructure to support specialized gene therapies are driving this increase. In addition, personalized medicine is becoming increasingly popular among patients, and hospitals are responding by providing more tailored and effective treatment alternatives.
In The Region, The North American Gene-To-Patient Market Holds A Significant Revenue Share.
The North American gene-to-patient market is projected to have the largest market revenue share in the foreseeable future. It can be attributed to the high frequency of genetic problems, a well-developed healthcare system, substantial funding for biotechnology research and development, and enabling regulatory regulations. This region's emphasis on cutting-edge, individualized healthcare is a key factor in its growing market growth. In addition, Europe is estimated to grow rapidly in the global gene-to-patient market due to the region's huge population, rising need for quality healthcare, and the rise in health awareness among the populace. Rising efforts by the government to promote innovative medicines and in need of cutting-edge healthcare technology.
Recent Developments:
- In March 2024, Merck, a frontrunner in the scientific and technological industries, introduced the world to the first comprehensive, laboratory-validated genetic stability test. Accelerating biosafety assessment and the transition into commercial production, the Aptegra CHO genetic stability assay utilizes whole genome sequencing and bioinformatics.
Gene-to-Patient Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 134.6 Bn |
|
Revenue Forecast In 2031 |
USD 341.4 Bn |
|
Growth Rate CAGR |
CAGR of 12.5% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type, Application, End-User, Technology, And Distribution Channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Illumina, Thermo Fisher Scientific, Roche Diagnostics, Qiagen, BioRad Laboratories, Abbott Laboratories, PerkinElmer, Invitae, Myriad Genetics, Guardant Health, Foundation Medicine, Genomic Health, Agilent Technologies, Laboratory Corporation of America (LabCorp), Exact Sciences and Other Market Players |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
